Development of a Synthetic Surfactant Using a Surfactant Protein-C Peptide Analog: In Vitro Studies of Surface Physical Properties
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose: Pulmonary surfactant (PS) replacement has been the gold standard therapy for neonatal respiratory distress syndrome; however, almost all commercial PSs contain animal proteins. We prepared a synthetic PS by using a human surfactant protein (SP) analog and evaluated its in vitro properties. Materials and Methods: A peptide sequence (CPVHLKRLLLLLLLLLLLLLLLL) of human SP-C was chosen to develop the peptideanalog (SPa-C). The new synthetic SP-C PS (sSP-C PS) was synthesized from SPa-C, dipalmitoyl phosphatidylcholine, phosphatidylglycerol, and palmitic acid. Physical properties of the sSP-C PS were evaluated by measuring the maximum and minimumsurface tensions (STs), surfactant spreading, and adsorption rate. In addition, we recorded an ST-area diagram. The data obtained on sSP-C PS were subsequently compared with those of purified natural bovine surfactant (PNBS), and the commercial product, Surfacten®. Results: The sSP-C PS and Surfacten® were found to have maximum ST values of 32–33 mN/m, whereas that of PNBS was much lower at 19 mN/m. The minimum ST values of all three products were less than 10 mN/m. The values that were measured for the equilibrium ST of rapidly spreading sSP-C PS, Surfacten®, and PNBS were 27, 27, and 24 mN/m, respectively. The surface adsorptionswere found to be the same for all three PSs (20 mN/m). ST-area diagrams of sSP-C PS and Surfacten® revealed similar properties. Conclusion: In an in vitro experiment, the physical properties exhibited by sSP-C PS were similar to those of Surfacten®. Further study is required to evaluate the in vivo efficacy.
Abstract
Purpose: Pulmonary surfactant (PS) replacement has been the gold standard therapy for neonatal respiratory distress syndrome; however, almost all commercial PSs contain animal proteins. We prepared a synthetic PS by using a human surfactant protein (SP) analog and evaluated its in vitro properties. Materials and Methods: A peptide sequence (CPVHLKRLLLLLLLLLLLLLLLL) of human SP-C was chosen to develop the peptideanalog (SPa-C). The new synthetic SP-C PS (sSP-C PS) was synthesized from SPa-C, dipalmitoyl phosphatidylcholine, phosphatidylglycerol, and palmitic acid. Physical properties of the sSP-C PS were evaluated by measuring the maximum and minimumsurface tensions (STs), surfactant spreading, and adsorption rate. In addition, we recorded an ST-area diagram. The data obtained on sSP-C PS were subsequently compared with those of purified natural bovine surfactant (PNBS), and the commercial product, Surfacten®. Results: The sSP-C PS and Surfacten® were found to have maximum ST values of 32–33 mN/m, whereas that of PNBS was much lower at 19 mN/m. The minimum ST values of all three products were less than 10 mN/m. The values that were measured for the equilibrium ST of rapidly spreading sSP-C PS, Surfacten®, and PNBS were 27, 27, and 24 mN/m, respectively. The surface adsorptionswere found to be the same for all three PSs (20 mN/m). ST-area diagrams of sSP-C PS and Surfacten® revealed similar properties. Conclusion: In an in vitro experiment, the physical properties exhibited by sSP-C PS were similar to those of Surfacten®. Further study is required to evaluate the in vivo efficacy.
참고문헌 (41)
- Sweet DG, "European consensus guidelines on the management of neonatal respiratory distress syndrome in preterm infants--2013 update", Neonatology, 103, pp.353~368 (2013)
- Soll R, "Multiple versus single doses of exogenous surfactant for the prevention or treatment of neonatal respiratory distress syndrome", Cochrane Database Syst Rev, (1), pp.CD000141~ (2009)
- Halliday HL, "Surfactants: past, present and future", J Perinatol, 28(Suppl 1), pp.S47~S56 (2008)
- Bae CW, "Surfactant replacement therapy in neonates with respiratory distress syndrome: a collective evaluation of trials from 16 hospitals", J Korean Pediatr Soc, 36, pp.244~265 (1993)
- Bae CW, "Surfactant replacement therapy in RDS: a collaborative study of multi-center trials in Korea", J Korean Soc Neonatol, 4, pp.124~135 (1997)
- 배종우, "신생아 호흡곤란 증후군에서 인공 폐 표면활성제 보충요법 제 3보고 : 지난 15년간 한국에서의 치료 결과", Korean Journal of Pediatrics, 47(9), pp.940~948 (2004), 대한소아과학회
- 배종우, "Surfactant Therapy for Neonatal Respiratory Distress Syndrome: A Review of Korean Experiences over 17 Years", Journal of Korean Medical Science, 24(6), pp.1110~1118 (2009), 대한의학회
- 배종우, "2010년 전국 72개 병원에서 신생아 호흡곤란증후군의 폐 표면활 성제 치료 결과: 지난 20년간의 비교", Neonatal medicine, 18(2), pp.409~411 (2011), 대한신생아학회
- 김성미, "Early Prophylactic versus Late Selective Use of Surfactant for Respiratory Distress Syndrome in Very Preterm Infants: A Collaborative Study of 53 Multi-Center Trials in Korea", Journal of Korean Medical Science, 29(8), pp.1126~1131 (2014), 대한의학회
- Moya FR, "A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants", Pediatrics, 115, pp.1018~1029 (2005)
- Davis AJ, "Lung function in premature lambs and rabbits treated with a recombinant SP-C surfactant", Am J Respir Crit Care Med, 157, pp.553~559 (1998)
- Pfister RH, "New synthetic surfactants: the next generation?", Biol Neonate, 87, pp.338~344 (2005)
- Almlén A, "Synthetic surfactant based on analogues of SP-B and SP-C is superior to single-peptide surfactants in ventilated premature rabbits", Neonatology, 98, pp.91~99 (2010)
- Seehase M, "New surfactant with SP-B and C analogs gives survival benefit after inactivation in preterm lambs", PLoS One, 7, pp.e47631~ (2012)
- Otsubo E, "Characterization of synthetic lung surfactant activity against proinflammatory cytokines in human monocytes", Biol Pharm Bull, 25, pp.312~317 (2002)
- Bae CW, "Purification of bovine lung natural surfactant and assessment of surface physical properties", J Korean Med Assoc, 34, pp.534~544 (1991)
- Fujiwara T, "Surfactant replacement therapy with a single postventilatory dose of a reconstituted bovine surfactant in preterm neonates with respiratory distress syndrome: final analysis of a multicenter, double-blind, randomized trial and comparison with similar trials", The surfactant-TA study group. Pediatrics, 86, pp.753~764 (1990)
- Takei T, "The surface properties of chemically synthesized peptides analogous to human pulmonary surfactant protein SP-C", Biol Pharm Bull, 19, pp.1247~1253 (1996)
- Kang JH, "Preparation and in vitro physical activities of crude natural surfactant and artificial pulmonary surfactant containing synthetic peptide and phospholipid mixtures", J Korean Pediatr Soc, 41, pp.472~480 (1998)
- Shelley SA, "Purification of surfactant from lung washings and washings contaminated with blood constituents", Lipids, 12, pp.505~510 (1977)
- Fujiwara T, "Pulmonary surfactant: from molecular biology to clinical practice", pp.561~592 (1992), Elservier
- Sweet DG, "European consensus guidelines on the management of neonatal respiratory distress syndrome in preterm infants - 2010 update", Neonatology, 97, pp.402~417 (2010)
- Ma CC, "The role of surfactant in respiratory distress syndrome", Open Respir Med J, 6, pp.44~53 (2012)
- Ramanathan R, "Animal-derived surfactants: where are we? The evidence from randomized, controlled clinical trials", J Perinatol, 29(Suppl 2), pp.S38~S43 (2009)
- Soll RF, "Natural surfactant extract versus synthetic surfactant for neonatal respiratory distress syndrome", Cochrane Database Syst Rev, (2), pp.CD000144~ (2001)
- Kirsten GF, "The outcome of ELBW infants treated with NCPAP and In-SurE in a resource-limited institution", Pediatrics, 129, pp.e952~e959 (2012)
- 전가원, "Efficacy of Surfactant-TA, Calfactant and Poractant Alfa for Preterm Infants with Respiratory Distress Syndrome: A Retrospective Study", Yonsei Medical Journal, 56(2), pp.433~439 (2015), 연세대학교의과대학[DOI]
- Seger N, "Animal derived surfactant extract for treatment of respiratory distress syndrome", Cochrane Database Syst Rev, (2), pp.CD007836~ (2009)
- Soll RF, "Prophylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infants", Cochrane Database Syst Rev, (2), pp.CD000510~ (2001)
- Bahadue FL, "Early versus delayed selective surfactant treatment for neonatal respiratory distress syndrome", Cochrane Database Syst Rev, 11, pp.CD001456~ (2012)
- Stevens TP, "Early surfactant administration with brief ventilation vs. selective surfactant and continued mechanical ventilation for preterm infants with or at risk for respiratory distress syndrome", Cochrane Database Syst Rev, (4), pp.CD003063~ (2007)
- 김영돈, "신생아 호흡곤란증 치료를 위한 새로운 합성 표면활성제", Neonatal medicine, 19(4), pp.184~194 (2012), 대한신생아학회
- Curstedt T, "New synthetic surfactants--basic science", Biol Neonate, 87, pp.332~337 (2005)
- Spragg RG, "Treatment of acute respiratory distress syndrome with recombinant surfactant protein C surfactant", Am J Respir Crit Care Med, 167, pp.1562~1566 (2003)
- Spragg RG, "Effect of recombinant surfactant protein C-based surfactant on the acute respiratory distress syndrome", N Engl J Med, 351, pp.884~892 (2004)
- Curstedt T, "Surfactant protein C: basics to bedside", J Perinatol, 25(Suppl 2), pp.S36~S38 (2005)
- Johansson J, "Secondary structure and biophysical activity of synthetic analogues of the pulmonary surfactant polypeptide SP-C", Biochem J, 307(Pt 2), pp.535~541 (1995)
- Nilsson G, "Synthetic peptide-containing surfactants--evaluation of transmembrane versus amphipathic helices and surfactant protein C poly-valyl to poly-leucyl substitution", Eur J Biochem, 255, pp.116~124 (1998)
- Takei T, "Characterization of poly-leucine substituted analogues of the human surfactant protein SP-C", Biol Pharm Bull, 19, pp.1550~1555 (1996)
- Otsubo E, "Effects of the human pulmonary surfactant protein-C (SP-C), SP-CL16(6-28) on surface activities of surfactants with various phospholipids", Biol Pharm Bull, 25, pp.1303~1306 (2002)
- Fujiwara T, "Artificial surfactant therapy in hyaline-membrane disease", Lancet, 1, pp.55~59 (1980)